|
1
|
Mendes I and Vale N: Overcoming
microbiome-acquired gemcitabine resistance in pancreatic ductal
adenocarcinoma. Biomedicines. 12:2272024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen Y, Nian F, Chen J, Jiang Q, Yuan T,
Feng H, Shen X and Dong L: Metagenomic microbial signatures for
noninvasive detection of pancreatic cancer. Biomedicines.
13:10002025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grossberg AJ, Chu LC, Deig CR, Fishman EK,
Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM,
et al: Multidisciplinary standards of care and recent progress in
pancreatic ductal adenocarcinoma. CA Cancer J Clin. 70:375–403.
2020.PubMed/NCBI
|
|
4
|
Li K, Xiao Y, Bian J, Han L, He C, El-Omar
E, Gong L and Wang M: Ameliorative effects of gut microbial
metabolite urolithin A on pancreatic diseases. Nutrients.
14:25492022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eid M, Martínek A, Dolina J, Uvírová M and
Dítě P: Gut microbiome and pancreatic cancer. Klin Onkol. 37:20–26.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arsenijevic T, Nicolle R, Bouchart C,
D'Haene N, Demetter P, Puleo F and Van Laethem JL: Pancreatic
cancer meets human microbiota: Close encounters of the third kind.
Cancers (Basel). 13:12312021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scarà S, Bottoni P and Scatena R: CA 19-9:
Biochemical and clinical aspects. Adv Exp Med Biol. 867:247–260.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen MJ, Jamali A and Katona BW:
Challenges of early detection of pancreatic cancer. J Clin Invest.
135:e1919422025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tan X, Wang Y and Gong T: The interplay
between oral microbiota, gut microbiota and systematic diseases. J
Oral Microbiol. 15:22131122023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang W, Zhang K, Zhang P, Zheng J, Min C
and Li X: Research progress of pancreas-related microorganisms and
pancreatic cancer. Front Oncol. 10:6045312020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dhar AK: Human microbiome modulation: A
potential therapeutic strategy for pancreatic cancer. Synbiotics
for the Management of Cancer. Mishra N, Bhatt S, Paudel KR, Hansbro
PM and Dua K: Springer Nature Singapore; Singapore: pp. 205–242.
2023, View Article : Google Scholar
|
|
12
|
Wensel CR, Pluznick JL, Salzberg SL and
Sears CL: Next-generation sequencing: Insights to advance clinical
investigations of the microbiome. J Clin Invest. 132:e1549442022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jankowski WM, Fichna J and
Tarasiuk-Zawadzka A: A systematic review of the relationship
between gut microbiota and prevalence of pancreatic diseases.
Microb Pathog. 199:1072142025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sexton RE, Uddin MH, Bannoura S, Khan HY,
Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A,
et al: Connecting the human microbiome and pancreatic cancer.
Cancer Metastasis Rev. 41:317–331. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu Q, Jobin C and Thomas RM: Implications
of the microbiome in the development and treatment of pancreatic
cancer: Thinking outside of the box by looking inside the gut.
Neoplasia. 23:246–256. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kartal E, Schmidt TSB, Molina-Montes E,
Rodríguez-Perales S, Wirbel J, Maistrenko OM, Akanni WA, Alashkar
Alhamwe B, Alves RJ, Carrato A, et al: A faecal microbiota
signature with high specificity for pancreatic cancer. Gut.
71:1359–1372. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Qian C, Wang T, Jiang Y, Zhou Y,
Liu K, Ma Z, Liu P, Wu Y, Chen L, et al: A combination of faecal
and intratumour microbial community profiling reveals novel
diagnostic and prognostic biomarkers for pancreatic tumours. Clin
Transl Med. 14:e17262024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li P, Zhang H and Dai M: Current status
and prospect of gut and oral microbiome in pancreatic cancer:
Clinical and translational perspectives. Cancer Lett.
604:2172742024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Michaud DS and Izard J: Microbiota, oral
microbiome, and pancreatic cancer. Cancer J. 20:203–206. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fan X, Alekseyenko AV, Wu J, Peters BA,
Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R,
Miller G, et al: Human oral microbiome and prospective risk for
pancreatic cancer: A population-based nested case-control study.
Gut. 67:120–127. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagata N, Nishijima S, Kojima Y, Hisada Y,
Imbe K, Miyoshi-Akiyama T, Suda W, Kimura M, Aoki R, Sekine K, et
al: Metagenomic identification of microbial signatures predicting
pancreatic cancer from a multinational study. Gastroenterology.
163:222–238. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Michaud DS, Izard J, Wilhelm-Benartzi CS,
You DH, Grote VA, Tjønneland A, Dahm CC, Overvad K, Jenab M,
Fedirko V, et al: Plasma antibodies to oral bacteria and risk of
pancreatic cancer in a large European prospective cohort study.
Gut. 62:1764–1770. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim B, Oh S, Yang S, Ahn J, Jung K, Lee
JC, Hwang JH, Shin CM, Lee HJ, Lee HS, et al: Distinct microbiome
composition and reduced interactions in patients with pancreatic
cancer. Front Microbiol. 16:15554792025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sono M, Iimori K, Nagao M, Ogawa S, Maruno
T, Nakanishi Y, Anazawa T, Nagai K, Masui T, Mori H, et al:
Reduction of butyrate-producing bacteria in the gut microbiome of
Japanese patients with pancreatic cancer. Pancreatology.
24:1031–1039. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin D, Jin S, Zhou T, Cui Z, Guo B, Li G
and Zhang C: Quantitative evaluation of gut microbiota composition
in pancreatic cancer: A pooled study. Medicine (Baltimore).
103:e386082024.PubMed/NCBI
|
|
26
|
Chen T, Li X, Li G, Liu Y, Huang X, Ma W,
Qian C, Guo J, Wang S, Qin Q and Liu S: Alterations of commensal
microbiota are associated with pancreatic cancer. Int J Biol
Markers. 38:263–274. 2023. View Article : Google Scholar
|
|
27
|
Hashimoto S, Tochio T, Funasaka K,
Funahashi K, Hartanto T, Togashi Y, Saito M, Nishimoto Y, Yoshinori
M, Nakaoka K, et al: Changes in intestinal bacteria and imbalances
of metabolites induced in the intestines of pancreatic ductal
adenocarcinoma patients in a Japanese population: A preliminary
result. Scand J Gastroenterol. 58:193–198. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kohi S, Macgregor-Das A, Dbouk M, Yoshida
T, Chuidian M, Abe T, Borges M, Lennon AM, Shin EJ, Canto MI and
Goggins M: Alterations in the duodenal fluid microbiome of patients
with pancreatic cancer. Clin Gastroenterol Hepatol. 20:e196–e227.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sammallahti H, Rezasoltani S, Pekkala S,
Kokkola A, Asadzadeh Agdaei H, Azizmohammad Looha M, Ghanbari R,
Zamani F, Sadeghi A, Sarhadi VK, et al: Fecal profiling reveals a
common microbial signature for pancreatic cancer in Finnish and
Iranian cohorts. Gut Pathog. 17:242025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang J, Ma Y, Tan Q, Zhou B, Yu D, Jin M,
Zhang T, Liu J and Liu H: Gut Streptococcus is a microbial marker
for the occurrence and liver metastasis of pancreatic cancer. Front
Microbiol. 14:11610682023.
|
|
31
|
Yousefi B, Mohammadlou M, Aisa B,
Falalyeyeva T, Kobyliak N and Eslami M: Immunomodulatory role of
Faecalibacterium prausnitzii in obesity and metabolic
disorders. Minerva Biotechnol Biomol Res. 33:76–85. 2021.
|
|
32
|
Villani A, Fontana A, Panebianco C, Ferro
C, Copetti M, Pavlovic R, Drago D, Fiorentini C, Terracciano F,
Bazzocchi F, et al: A powerful machine learning approach to
identify interactions of differentially abundant gut microbial
subsets in patients with metastatic and non-metastatic pancreatic
cancer. Gut Microbes. 16:23754832024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matsukawa H, Iida N, Kitamura K, Terashima
T, Seishima J, Makino I, Kannon T, Hosomichi K, Yamashita T, Sakai
Y, et al: Dysbiotic gut microbiota in pancreatic cancer patients
form correlation networks with the oral microbiota and prognostic
factors. Am J Cancer Res. 11:3163–3175. 2021.PubMed/NCBI
|
|
34
|
Kharofa J, Haslam D, Wilkinson R, Weiss A,
Patel S, Wang K, Esslinger H, Olowokure O, Sohal D, Wilson G, et
al: Analysis of the fecal metagenome in long-term survivors of
pancreas cancer. Cancer. 129:1986–1994. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Świdnicka-Siergiejko A, Daniluk J,
Miniewska K, Daniluk U, Guzińska-Ustymowicz K, Pryczynicz A,
Dąbrowska M, Rusak M, Ciborowski M and Dąbrowski A: Inflammatory
stimuli and fecal microbiota transplantation accelerate pancreatic
carcinogenesis in transgenic mice, accompanied by changes in the
microbiota composition. Cells. 14:3612025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Riquelme E, Zhang Y, Zhang L, Montiel M,
Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, et
al: Tumor microbiome diversity and composition influence pancreatic
cancer outcomes. Cell. 178:795–806.e12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Genton L, Lazarevic V, Stojanovic O,
Spiljar M, Djaafar S, Koessler T, Dutoit V, Gaïa N, Mareschal J,
Macpherson AJ, et al: Metataxonomic and metabolic impact of fecal
microbiota transplantation from patients with pancreatic cancer
into germ-free mice: A pilot study. Front Cell Infect Microbiol.
11:7528892021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong TS, Chang HH, Hauer M, Lagishetty V,
Katzka W, Rozengurt E, Jacobs JP and Eibl G: Metformin alters the
duodenal microbiome and decreases the incidence of pancreatic
ductal adenocarcinoma promoted by diet-induced obesity. Am J
Physiol Gastrointest Liver Physiol. 317:G763–G772. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li ZY, Chen SY, Weng MH and Yen GC:
Ursolic acid restores sensitivity to gemcitabine through the
RAGE/NF-κB/MDR1 axis in pancreatic cancer cells and in a mouse
xenograft model. J Food Drug Anal. 29:262–274. 2021.PubMed/NCBI
|
|
40
|
Knight R, Vrbanac A, Taylor BC, Aksenov A,
Callewaert C, Debelius J, Gonzalez A, Kosciolek T, McCall LI,
McDonald D, et al: Best practices for analysing microbiomes. Nat
Rev Microbiol. 16:410–422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gao YC, Zhou DD, Lu YB, Yang L, Gong XJ,
Chen MY, Liang S, Huang WH and Zhang W: Antitumor potentials of
onco-microbial in Chinese patients with pancreatic cancer. Heliyon.
10:e344202024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
May MS, Park H, Moallem DH, Seeram D,
Dajiang S, Hibshoosh H, Jamison JK, Uhlemann AC and Manji GA: Low
bacterial biomass in human pancreatic cancer and adjacent normal
tissue. Int J Mol Sci. 26:1402024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Salter SJ, Cox MJ, Turek EM, Calus ST,
Cookson WO, Moffatt MF, Turner P, Parkhill J, Loman NJ and Walker
AW: Reagent and laboratory contamination can critically impact
sequence-based microbiome analyses. BMC Biol. 12:872014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhu Y, Liang X, Zhang G, Li F, Xu J, Ma R,
Chen X, Ma M, Wang Y, Chen C, et al: Microbiota and metabolite
alterations in pancreatic head and body/tail cancer patients.
Cancer Sci. 115:2738–2750. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Chang RB, Stone ML, Delman D,
Markowitz K, Xue Y, Coho H, Herrera VM, Li JH, Zhang L, et al:
Multimodal immune phenotyping reveals microbial-T cell interactions
that shape pancreatic cancer. Cell Rep Med. 5:1013972024.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Halimi A, Gabarrini G, Sobkowiak MJ, Ateeb
Z, Davanian H, Gaiser RA, Arnelo U, Valente R, Wong AYW, Moro CF,
et al: Isolation of pancreatic microbiota from cystic precursors of
pancreatic cancer with intracellular growth and DNA damaging
properties. Gut Microbes. 13:19831012021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Stasiewicz M, Kwaśniewski M and Karpiński
TM: Microbial associations with pancreatic cancer: A new frontier
in biomarkers. Cancers (Basel). 13:37842021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Del Castillo E, Meier R, Chung M, Koestler
DC, Chen T, Paster BJ, Charpentier KP, Kelsey KT, Izard J and
Michaud DS: The microbiomes of pancreatic and duodenum tissue
overlap and are highly subject specific but differ between
pancreatic cancer and noncancer subjects. Cancer Epidemiol
Biomarkers Prev. 28:370–383. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu Y, Liang X, Zhi M, Li L, Zhang G, Chen
C, Wang L, Wang P, Zhong N, Feng Q and Li Z: Succession of the
multi-site microbiome along pancreatic ductal adenocarcinoma
tumorigenesis. Front Immunol. 15:14872422024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guo X and Shao Y: Role of the oral-gut
microbiota axis in pancreatic cancer: A new perspective on tumor
pathophysiology, diagnosis, and treatment. Mol Med. 31:1032025.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
McAllister F, Khan MAW, Helmink B and
Wargo JA: The tumor microbiome in pancreatic cancer: Bacteria and
beyond. Cancer Cell. 36:577–579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Karpiński TM: The microbiota and
pancreatic cancer. Gastroenterol Clin North Am. 48:447–464. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yuan M, Xu Y and Guo Z: Association of
oral microbiome and pancreatic cancer: A systematic review and
meta-analysis. Ther Adv Gastroenterol. 15:175628482211239802022.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Merali N, Chouari T, Terroire J, Jessel
MD, Liu DSK, Smith JH, Wooldridge T, Dhillon T, Jiménez JI, Krell
J, et al: Bile microbiome signatures associated with pancreatic
ductal adenocarcinoma compared to benign disease: A UK pilot study.
Int J Mol Sci. 24:168882023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Poudel SK, Padmanabhan R, Dave H, Guinta
K, Stevens T, Sanaka MR, Chahal P, Sohal DPS, Khorana AA and Eng C:
Microbiomic profiles of bile in patients with benign and malignant
pancreaticobiliary disease. PLoS One. 18:e02830212023. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Eisenhofer R, Minich JJ, Marotz C, Cooper
A, Knight R and Weyrich LS: Contamination in low microbial biomass
microbiome studies: Issues and recommendations. Trends Microbiol.
27:105–117. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Merali N, Chouari T, Sweeney C,
Halle-Smith J, Jessel MD, Wang B, O' Brien J, Suyama S, Jiménez JI,
Roberts KJ, et al: The microbial composition of pancreatic ductal
adenocarcinoma: A systematic review of 16S rRNA gene sequencing.
Int J Surg. 110:6771–6799. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kartal E, Schmidt TSB, Molina-Montes E,
Rodríguez-Perales S, Wirbel J, Maistrenko OM, Akanni WA, Alashkar
Alhamwe B, Alves RJ, Carrato A, et al: A faecal microbiota
signature with high specificity for pancreatic cancer. Gut.
71:1359–1372. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Farrell JJ, Zhang L, Zhou H, Chia D,
Elashoff D, Akin D, Paster BJ, Joshipura K and Wong DT: Variations
of oral microbiota are associated with pancreatic diseases
including pancreatic cancer. Gut. 61:582–588. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Guo X, Hu Z, Rong S, Xie G, Nie G, Liu X
and Jin G: Integrative analysis of metabolome and gut microbiota in
patients with pancreatic ductal adenocarcinoma. J Cancer.
13:1555–1564. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li P, Zhang H, Chen L, Gao X, Hu Y, Xu Q,
Liu W, Chen W, Chen H, Yuan S, et al: Oral and fecal microbiota as
accurate non-invasive tools for detection of pancreatic cancer in
the Chinese population. Cancer Lett. 612:2174562025. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhou W, Zhang D, Li Z, Jiang H, Li J, Ren
R, Gao X, Li J, Wang X, Wang W and Yang Y: The fecal microbiota of
patients with pancreatic ductal adenocarcinoma and autoimmune
pancreatitis characterized by metagenomic sequencing. J Transl Med.
19:2152021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang P, Shi H, Guo R, Li L, Guo X, Yang
H, Chang D, Cheng Y, Zhao G, Li S, et al: Metagenomic analysis
reveals altered gut virome and diagnostic potential in pancreatic
cancer. J Med Virol. 96:e298092024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wong DT, Zhang L, Farrell J, Zhou H,
Elashoff D, Gao K and Paster BJ: Salivary biomarkers for pancreatic
cancer detection. J Clin Oncol. 27 (15 Suppl):S46292009. View Article : Google Scholar
|
|
65
|
Wei AL, Li M, Li GQ, Wang X, Hu WM, Li ZL,
Yuan J, Liu HY, Zhou LL, Li K, et al: Oral microbiome and
pancreatic cancer. World J Gastroenterol. 26:7679–7692. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ammer-Herrmenau C, Pfisterer N, Weingarten
MF and Neesse A: The microbiome in pancreatic diseases: Recent
advances and future perspectives. United European Gastroenterol J.
8:878–885. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kaźmierczak-Siedlecka K, Stachowska E,
Folwarski M, Przewłócka K, Makarewicz W and Bryl E: The potential
of gut microbiome as a non-invasive predictive biomarker for early
detection of pancreatic cancer and hepatocellular carcinoma. Eur
Rev Med Pharmacol Sci. 25:7275–7284. 2021.PubMed/NCBI
|
|
68
|
Wei X, Mei C, Li X and Xie Y: The unique
microbiome and immunity in pancreatic cancer. Pancreas. 50:119–129.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li JJ, Zhu M, Kashyap PC, Chia N, Tran NH,
McWilliams RR, Bekaii-Saab TS and Ma WW: The role of microbiome in
pancreatic cancer. Cancer Metastasis Rev. 40:777–789. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Miyabayashi K, Ijichi H and Fujishiro M:
The role of the microbiome in pancreatic cancer. Cancers (Basel).
14:44792022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Marcos-Zambrano LJ, Karaduzovic-Hadziabdic
K, Loncar Turukalo T, Przymus P, Trajkovik V, Aasmets O, Berland M,
Gruca A, Hasic J, Hron K, et al: Applications of machine learning
in human microbiome studies: A review on feature selection,
biomarkeridentification, disease prediction and treatment. Front
Microbiol. 12:6345112021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cortez NE, Rodriguez Lanzi C, Hong BV, Xu
J, Wang F, Chen S, Ramsey JJ, Pontifex MG, Müller M, Vauzour D, et
al: A ketogenic diet in combination with gemcitabine increases
survival in pancreatic cancer KPC mice. Cancer Res Commun.
2:951–965. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Li P, Zhang H, Gao X, Chen L, Chen H, Yuan
S, Chen W and Dai M: Difference in fecal and oral microbiota
between pancreatic cancer and benign/low-grade malignant tumor
patients. BMC Microbiol. 24:5272024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Pourali G, Kazemi D, Chadeganipour AS,
Arastonejad M, Kashani SN, Pourali R, Maftooh M, Akbarzade H, Fiuji
H, Hassanian SM, et al: Microbiome as a biomarker and therapeutic
target in pancreatic cancer. BMC Microbiol. 24:162024. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Khan ZA, Ghorbani M, Heffinger L,
Damdimopoulos A, Moro CF, Björnstedt M, Löhr JM, Heuchel R, Chen MS
and Sarhan D: Genderized gut and oral microbiome shifts: Uncovering
sex-specific dysbiosis in pancreatic cancer. bioRxiv. Oct
3–2024.doi: 10.1101/2024.10.02.616338.
|
|
76
|
Li Z, Chu J, Su F, Ding X, Zhang Y, Dou L,
Liu Y, Ke Y, Liu X, Liu Y, et al: Characteristics of bile
microbiota in cholelithiasis, perihilar cholangiocarcinoma, distal
cholangiocarcinoma, and pancreatic cancer. Am J Transl Res.
14:2962–2971. 2022.PubMed/NCBI
|
|
77
|
Sethi V, Tao J, Kurtom S, Vaish U, Afaq F,
Zao S, Luo X, Jain T, Sharma P, Bava E, et al: Abstract 3046: A
common gut commensal utilizes tryptophan to promote cancer via the
aryl hydrocarbon receptor. Cancer Res. 82 (12 Suppl):S30462022.
View Article : Google Scholar
|
|
78
|
Subramanian I, Verma S, Kumar S, Jere A
and Anamika K: Multi-omics data integration, interpretation, and
its application. Bioinform Biol Insights. 14:11779322198990512020.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhang L, Sanagapalli S and Stoita A:
Challenges in diagnosis of pancreatic cancer. World J
Gastroenterol. 24:2047–2060. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Singhi AD, Koay EJ, Chari ST and Maitra A:
Early detection of pancreatic cancer: Opportunities and challenges.
Gastroenterology. 156:2024–2040. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Poruk KE, Firpo MA, Adler DG and Mulvihill
SJ: Screening for pancreatic cancer: Why, how, and who? Ann Surg.
257:17–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wirbel J, Zych K, Essex M, Karcher N,
Kartal E, Salazar G, Bork P, Sunagawa S and Zeller G: Microbiome
meta-analysis and cross-disease comparison enabled by the SIAMCAT
machine learning toolbox. Genome Biol. 22:932021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Steyerberg EW, Vickers AJ, Cook NR, Gerds
T, Gonen M, Obuchowski N, Pencina MJ and Kattan MW: Assessing the
performance of prediction models: A framework for traditional and
novel measures. Epidemiology. 21:128–138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Van Smeden M, Reitsma JB, Riley RD,
Collins GS and Moons KGM: Clinical prediction models: Diagnosis
versus prognosis. J Clin Epidemiol. 132:142–145. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Asnicar F, Thomas AM, Passerini A, Waldron
L and Segata N: Machine learning for microbiologists. Nat Rev
Microbiol. 22:191–205. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Bastos AR, Pereira-Marques J, Ferreira RM
and Figueiredo C: Harnessing the microbiome to reduce pancreatic
cancer burden. Cancers (Basel). 15:26292023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Abdul Rahman R, Lamarca A, Hubner RA,
Valle JW and McNamara MG: The microbiome as a potential target for
therapeutic manipulation in pancreatic cancer. Cancers (Basel).
13:37792021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li P, Shu Y and Gu Y: The potential role
of bacteria in pancreatic cancer: A systematic review.
Carcinogenesis. 41:397–404. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Memba R, Duggan SN, Ni Chonchubhair HM,
Griffin OM, Bashir Y, O'Connor DB, Murphy A, McMahon J, Volcov Y,
Ryan BM and Conlon KC: The potential role of gut microbiota in
pancreatic disease: A systematic review. Pancreatology. 17:867–874.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Meng C, Bai C, Brown TD, Hood L and Tian
Q: Human gut microbiota and gastrointestinal cancer. Genomics
Proteomics Bioinformatics. 16:33–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Gong Y, Huang X, Wang M and Liang X:
Intratumor microbiota: A novel tumor component. J Cancer Res Clin
Oncol. 149:6675–6691. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wright RD, Bartelli TF, Baydogan S, White
JR, Kim MP, Bhutani MS and McAllister F: Bacterial and fungal
characterization of pancreatic adenocarcinoma from endoscopic
ultrasound-guided biopsies. Front Immunol. 14:12683762023.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Thomas RM, Gharaibeh RZ, Gauthier J,
Beveridge M, Pope JL, Guijarro MV, Yu Q, He Z, Ohland C, Newsome R,
et al: Intestinal microbiota enhances pancreatic carcinogenesis in
preclinical models. Carcinogenesis. 39:1068–1078. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zmora N, Suez J and Elinav E: You are what
you eat: Diet, health and the gut microbiota. Nat Rev Gastroenterol
Hepatol. 16:35–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Tong Y, Gao H, Qi Q, Li J, Gao J, Li P,
Wang Y, Du L and Wang C: High fat diet, gut microbiome and
gastrointestinal cancer. Theranostics. 11:5889–5910. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Dong L, Chen Y, Nian F, et al: Low-protein
diet enhances anti-tumor immunity and immunotherapy through
microbiota-derived uridine diphosphate-galactose in pancreatic
cancer. Res Sq [Preprint]. 2025.doi:
10.21203/rs.3.rs-5804694/v1.
|
|
97
|
Ruze R, Song J, Yin X, Chen Y, Xu R, Wang
C and Zhao Y: Mechanisms of obesity- and diabetes mellitus-related
pancreatic carcinogenesis: A comprehensive and systematic review.
Signal Transduct Target Ther. 8:1392023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kesh K, Mendez R, Abdelrahman L and
Banerjee S and Banerjee S: Type 2 diabetes-induced microbiome
dysbiosis is associated with therapy resistance in pancreatic
adenocarcinoma. Microb Cell Fact. 19:752020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Panebianco C, Adamberg K, Jaagura M,
Copetti M, Fontana A, Adamberg S, Kolk K, Vilu R, Andriulli A and
Pazienza V: Influence of gemcitabine chemotherapy on the microbiota
of pancreatic cancer xenografted mice. Cancer Chemother Pharmacol.
81:773–782. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Miller PL and Carson TL: Mechanisms and
microbial influences on CTLA-4- and PD-1-based immunotherapy in the
treatment of cancer: A narrative review. Gut Pathog. 12:432020.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Nalluri H, Jensen E and Staley C: Role of
biliary stent and neoadjuvant chemotherapy in the pancreatic tumor
microbiome. BMC Microbiol. 21:2802021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Takaori A, Hashimoto D, Ikeura T, Ito T,
Nakamaru K, Masuda M, Nakayama S, Yamaki S, Yamamoto T, Fujimoto K,
et al: Impact of neoadjuvant therapy on gut microbiome in patients
with resectable/borderline resectable pancreatic ductal
adenocarcinoma. Pancreatology. 23:367–376. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Sawada K, Yamashita R, Sakai SA, Horasawa
S, Yoshikawa A, Fujisawa T, Kadowaki S, Kato K, Ueno M, Oki E, et
al: Microbiome landscape and association with response to immune
checkpoint inhibitors in advanced solid tumors: A SCRUM-Japan
MONSTAR-SCREEN study. Cancer Res Commun. 5:857–870. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Nalluri H, Staley C and Jensen EH:
Abstract 6097: Alterations of the pancreatic tumor microbiome: The
role of biliary stents. Cancer Res. 80 (16 Suppl):S60972020.
View Article : Google Scholar
|
|
105
|
Stein-Thoeringer CK, Renz BW, De Castilhos
J, von Ehrlich-Treuenstätt V, Wirth U, Tschaidse T, Hofmann FO,
Koch DT, Beirith I, Ormanns S, et al: Microbiome dysbiosis with
Enterococcus presence in the upper gastrointestinal tract is a risk
factor for mortality in patients undergoing surgery for pancreatic
cancer. Ann Surg. 281:615–625. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ni P, Li L, Du K, Nov P, Wang D, Wang C,
Kou Q, Li Y, Zhang Y, Zheng C, et al: Unveiling the immunological
terrain of pancreatic ductal adenocarcinoma: Strategies to prompt
immunotherapy from Mendelian randomization. Discov Oncol.
16:6132025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bracci PM: Oral health and the oral
microbiome in pancreatic cancer: An overview of epidemiological
studies. Cancer J. 23:310–314. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ho WJ, Jaffee EM and Zheng L: The tumour
microenvironment in pancreatic cancer: Clinical challenges and
opportunities. Nat Rev Clin Oncol. 17:527–540. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Langheinrich M, Wirtz S, Kneis B, Gittler
MM, Tyc O, Schierwagen R, Brunner M, Krautz C, Weber GF, Pilarsky
C, et al: Microbiome patterns in matched bile, duodenal, pancreatic
tumor tissue, drainage, and stool samples: Association with
preoperative stenting and postoperative pancreatic fistula
development. J Clin Med. 9:27852020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Frost F, Weiss FU and Lerch MM: The role
of the microbiome in diseases of the pancreas. Internist (Berl).
63:372–378. 2022.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Daniel N, Farinella R, Belluomini F,
Fajkic A, Rizzato C, Souček P, Campa D and Hughes DJ: The
relationship of the microbiome, associated metabolites and the gut
barrier with pancreatic cancer. Semin Cancer Biol. 112:43–57. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Hesami Z, Sabzehali F, Khorsand B, Alipour
S, Sadeghi A, Asri N, Pazienza V and Houri H: Microbiota as a
state-of-the-art approach in precision medicine for pancreatic
cancer management: A comprehensive systematic review. iScience.
28:1123142025. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
World Health Organization, . WHO Expert
Committee on Specifications for Pharmaceutical Preparations:
Forty-eighth report. World Health Organization; Geneva: 2014
|
|
114
|
Acharjee A, Singh U, Choudhury SP and
Gkoutos GV: The diagnostic potential and barriers of
microbiome-based therapeutics. Diagnosis (Berl). 9:411–420. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Adamo JE, Bienvenu RV, Fields FO, et al:
The integration of emerging omics approaches to advance precision
medicine: How can regulatory science help? J Clin Transl Sci.
2:295–300. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Porcari S, Mullish BH, Asnicar F, Ng SC,
Zhao L, Hansen R, O'Toole PW, Raes J, Hold G, Putignani L, et al:
International consensus statement on microbiome testing in clinical
practice. Lancet Gastroenterol Hepatol. 10:154–167. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Pandya G, Kirtonia A, Singh A, Goel A,
Mohan CD, Rangappa KS, Pandey AK, Kapoor S, Tandon S, Sethi G and
Garg M: A comprehensive review of the multifaceted role of the
microbiota in human pancreatic carcinoma. Semin Cancer Biol.
86:682–692. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Fan X, Jin Y, Chen G, Ma X and Zhang L:
Gut microbiota dysbiosis drives the development of colorectal
cancer. Digestion. 102:508–515. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Wei MY, Shi S, Liang C, Meng QC, Hua J,
Zhang YY, Liu J, Zhang B, Xu J and Yu XJ: The microbiota and
microbiome in pancreatic cancer: More influential than expected.
Mol Cancer. 18:972019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Tintelnot J, Xu Y, Lesker TR, Schönlein M,
Konczalla L, Giannou AD, Pelczar P, Kylies D, Puelles VG, Bielecka
AA, et al: Microbiota-derived 3-IAA influences chemotherapy
efficacy in pancreatic cancer. Nature. 615:168–174. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Lin Q, Guan SW and Yu HB:
Immuno-oncology-microbiome axis of gastrointestinal malignancy.
World J Gastrointest Oncol. 15:757–775. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Pushalkar S, Hundeyin M, Daley D,
Zambirinis CP, Kurz E, Mishra A, Mohan N, Aykut B, Usyk M, Torres
LE, et al: The pancreatic cancer microbiome promotes oncogenesis by
induction of innate and adaptive immune suppression. Cancer Discov.
8:403–416. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Luu M, Riester Z, Baldrich A, Reichardt N,
Yuille S, Busetti A, Klein M, Wempe A, Leister H, Raifer H, et al:
Microbial short-chain fatty acids modulate CD8+ T cell responses
and improve adoptive immunotherapy for cancer. Nat Commun.
12:40772021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Temel HY, Kaymak Ö, Kaplan S, Bahcivanci
B, Gkoutos GV and Acharjee A: Role of microbiota and
microbiota-derived short-chain fatty acids in PDAC. Cancer Med.
12:5661–5675. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Elango A, Nesam VD, Sukumar P, Lawrence I
and Radhakrishnan A: Postbiotic butyrate: Role and its effects for
being a potential drug and biomarker to pancreatic cancer. Arch
Microbiol. 206:1562024. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Mirji G, Worth A, Bhat SA, El Sayed M,
Kannan T, Goldman AR, Tang HY, Liu Q, Auslander N, Dang CV, et al:
The microbiome-derived metabolite TMAO drives immune activation and
boosts responses to immune checkpoint blockade in pancreatic
cancer. Sci Immunol. 7:eabn07042022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
León-Letelier RA, Dou R, Vykoukal J,
Yip-Schneider MT, Maitra A, Irajizad E, Wu R, Dennison JB, Do KA,
Zhang J, et al: Contributions of the microbiome-derived metabolome
for risk assessment and prognostication of pancreatic cancer. Clin
Chem. 70:102–115. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Vitiello GA, Cohen DJ and Miller G:
Harnessing the microbiome for pancreatic cancer immunotherapy.
Trends Cancer. 5:670–676. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Bartolini I, Nannini G, Risaliti M,
Matarazzo F, Moraldi L, Ringressi MN, Taddei A and Amedei A: Impact
of microbiota-immunity axis in pancreatic cancer management. World
J Gastroenterol. 28:4527–4539. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Sturque J, Berquet A, Loison-Robert LS,
Ahossi V and Zwetyenga N: Interest of studying the saliva
metabolome, transcriptome and microbiome in screening for
pancreatic cancer. J Stomatol Oral Maxillofac Surg. 120:554–558.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Cao C, Yue S, Lu A and Liang C: Host-Gut
microbiota metabolic interactions and their role in precision
diagnosis and treatment of gastrointestinal cancers. Pharmacol Res.
207:1073212024. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Konishi H, Isozaki S, Kashima S, Moriichi
K, Ichikawa S, Yamamoto K, Yamamura C, Ando K, Ueno N, Akutsu H, et
al: Probiotic Aspergillus oryzae produces anti-tumor mediator and
exerts anti-tumor effects in pancreatic cancer through the p38 MAPK
signaling pathway. Sci Rep. 11:110702021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Chen SM, Chieng WW, Huang SW, Hsu LJ and
Jan MS: The synergistic tumor growth-inhibitory effect of probiotic
Lactobacillus on transgenic mouse model of pancreatic cancer
treated with gemcitabine. Sci Rep. 10:203192020. View Article : Google Scholar : PubMed/NCBI
|
